A detailed history of D.A. Davidson & Co. transactions in Cel Sci Corp stock. As of the latest transaction made, D.A. Davidson & Co. holds 32,800 shares of CVM stock, worth $34,768. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,800
Previous 32,300 1.55%
Holding current value
$34,768
Previous $61,000 37.7%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$1.11 - $1.85 $555 - $925
500 Added 1.55%
32,800 $38,000
Q1 2024

May 13, 2024

SELL
$1.63 - $3.08 $421,563 - $796,574
-258,628 Reduced 88.9%
32,300 $61,000
Q4 2023

Feb 09, 2024

BUY
$1.07 - $3.07 $264,426 - $758,682
247,128 Added 564.22%
290,928 $791,000
Q3 2023

Nov 08, 2023

SELL
$1.17 - $2.86 $567,905 - $1.39 Million
-485,389 Reduced 91.72%
43,800 $54,000
Q2 2023

Aug 10, 2023

SELL
$2.11 - $2.83 $37,138 - $49,810
-17,601 Reduced 3.22%
529,189 $1.28 Million
Q1 2023

Apr 25, 2023

BUY
$2.17 - $3.13 $357,874 - $516,196
164,919 Added 43.19%
546,790 $1.27 Million
Q4 2022

Feb 03, 2023

SELL
$1.99 - $3.52 $173,945 - $307,683
-87,410 Reduced 18.63%
381,871 $897,000
Q3 2022

Nov 07, 2022

SELL
$3.09 - $5.23 $23,669 - $40,061
-7,660 Reduced 1.61%
469,281 $1.45 Million
Q2 2022

Jul 28, 2022

BUY
$2.58 - $4.99 $123,682 - $239,215
47,939 Added 11.17%
476,941 $2.15 Million
Q1 2022

May 12, 2022

BUY
$3.93 - $7.7 $154,142 - $302,009
39,222 Added 10.06%
429,002 $1.69 Million
Q4 2021

Jan 31, 2022

BUY
$7.1 - $12.82 $57,410 - $103,662
8,086 Added 2.12%
389,780 $2.77 Million
Q3 2021

Nov 15, 2021

BUY
$7.64 - $12.49 $333,791 - $545,688
43,690 Added 12.93%
381,694 $4.2 Million
Q2 2021

Aug 10, 2021

BUY
$8.68 - $27.49 $82,026 - $259,780
9,450 Added 2.88%
338,004 $2.93 Million
Q1 2021

May 07, 2021

BUY
$12.0 - $27.64 $211,392 - $486,906
17,616 Added 5.67%
328,554 $5 Million
Q4 2020

Feb 10, 2021

BUY
$11.05 - $16.62 $88,411 - $132,976
8,001 Added 2.64%
310,938 $3.63 Million
Q3 2020

Nov 02, 2020

BUY
$11.69 - $14.54 $765,858 - $952,573
65,514 Added 27.59%
302,937 $3.86 Million
Q2 2020

Aug 10, 2020

SELL
$9.75 - $17.6 $2.03 Million - $3.66 Million
-208,174 Reduced 46.72%
237,423 $3.54 Million
Q1 2020

May 05, 2020

SELL
$7.54 - $17.05 $402,666 - $910,538
-53,404 Reduced 10.7%
445,597 $5.14 Million
Q4 2019

Feb 14, 2020

SELL
$6.71 - $9.55 $198,072 - $281,906
-29,519 Reduced 5.59%
499,001 $4.57 Million
Q3 2019

Nov 05, 2019

BUY
$6.0 - $9.6 $65,520 - $104,832
10,920 Added 2.11%
528,520 $4.73 Million
Q2 2019

Aug 13, 2019

BUY
$3.77 - $8.67 $444,483 - $1.02 Million
117,900 Added 29.5%
517,600 $4.34 Million
Q1 2019

May 13, 2019

BUY
$2.58 - $3.54 $254,130 - $348,690
98,500 Added 32.7%
399,700 $1.42 Million
Q4 2018

Jan 29, 2019

BUY
$2.65 - $4.26 $427,180 - $686,712
161,200 Added 115.14%
301,200 $864,000
Q3 2018

Nov 13, 2018

BUY
$0.83 - $4.16 $116,200 - $582,400
140,000 New
140,000 $567,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $46M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track D.A. Davidson & Co. Portfolio

Follow D.A. Davidson & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.